Congress moves to block nitazene opioids before they spread further
H.R. 5415 — Nitazene Control Act of 2025 · Filed by Eugene Vindman (D-VA) · 30 cosponsors · Introduced Sep 16, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill permanently adds nitazenes—a class of synthetic opioids more potent than fentanyl—to Schedule I of the Controlled Substances Act, blocking their legal manufacture and use. The bill defines nitazenes by chemical structure and lists specific compounds, and converts any temporary scheduling already in place to permanent status, closing a legal loophole that allowed new analogs to be created and sold as the DEA scheduled them one by one.
Why we flagged it
The bill's sole operative mechanism is to add a class of dangerous synthetic opioids to Schedule I of the Controlled Substances Act, a straightforward public-health measure to prevent overdose deaths and close enforcement loopholes.
What the text implies
- The structural definition in subsection (a) is broad enough to capture future nitazene analogs without requiring new legislation, but relies on DEA interpretation of 'structurally related' and 'agonist activity'—enforcement may depend on regulatory guidance.
- Subsection (c) preserves research pathways under the HALT Fentanyl Act, meaning DEA-registered researchers can still study nitazenes; the bill does not eliminate all legal access, only commercial and recreational use.
- Permanent scheduling removes the temporary-scheduling loophole that allowed manufacturers to create and sell new analogs faster than the DEA could schedule them individually, but does not address the underlying supply-chain or precursor-chemical sourcing.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Nitazenes are potent synthetic opioids driving overdose deaths and have no accepted medical use; permanent scheduling prevents manufacturers from evading enforcement by creating new analogs. Citizens benefit from reduced illicit supply and faster law-enforcement response, though the bill preserves a research pathway under the HALT Fentanyl Act for legitimate scientific study.
Named in the bill
Drug Enforcement Administration (DEA), Controlled Substances Act, Schedule I, HALT Fentanyl Act, 2-benzylbenzimidazole opioids, nitazenes, etonitazene, isotonitazene, metonitazene
Where it stands
30 cosponsors: 21 Republicans, 9 Democrats.
- Sep 16, 2025 — Introduced · Congress.gov: “Introduced in House”
- Sep 16, 2025 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $32,750 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 41% of bills with at least one filing.
Eugene Vindman, the sponsor, reported $867,778 in PAC receipts in the 2026 cycle.
- Drug Policy Alliance — $18,639 on 1 filing
- The Sentencing Project — $14,111 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,275 characters) on Sep 23, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress moves to block nitazene opioids before they spread further” QuorumCivic. https://share.quorumcivic.app/bill/119/hr5415 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.